CDNAHealthcare · Diagnostics & ResearchThe 7 Wall Street analysts covering CareDx, Inc. hold a median 12-month price target of $91 — +6.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores CareDx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CDNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Oct 2026 | BTIG | Maintains | Buy | $81 → $92 |
| 27 Oct 2026 | BTIG | Maintains | Buy | $74 → $81 |
| 19 Oct 2026 | Canaccord Genuity | Maintains | Buy | $65 → $80 |
| 19 Oct 2026 | Canaccord Genuity | Maintains | Buy | — |
| 24 Sept 2026 | BTIG | Maintains | Buy | $60 → $74 |
| 24 Sept 2026 | BTIG | Maintains | Buy | — |
| 2 Sept 2026 | Canaccord Genuity | Initiates | Buy | $65 |
| 2 Sept 2026 | Canaccord Genuity | Initiates | Buy | — |
| 6 Aug 2026 | BTIG | Maintains | Buy | $45 → $60 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 31 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | $46 |
| 31 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 16 July 2026 | BTIG | Maintains | Buy | $28 → $45 |
| 16 July 2026 | BTIG | Maintains | Buy | — |
| 29 Apr 2026 | BTIG | Maintains | Buy | $26 → $28 |
| 29 Apr 2026 | BTIG | Maintains | Buy | — |
| 26 Feb 2026 | BTIG | Maintains | Buy | — |
| 25 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Dec 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 6 Nov 2025 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CDNA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, CareDx, Inc. returned +491.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 14% of US stocks
Cheaper than 9% of US stocks
Cheaper than 1% of US stocks
Higher than 83% of US stocks
Higher than 97% of US stocks
Higher than 86% of US stocks
Higher than 61% of US stocks
Higher than 86% of US stocks
Higher than 89% of US stocks
Higher than 49% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CareDx, Inc. has a market value of $4.7B and an enterprise value of $4.3B.
Revenue in the twelve months to 30 June 2026: $458.1M. The latest quarter grew 39.3% year on year.
Net income over the same four quarters: $111.0M, a 24.2% net margin.
Diluted earnings per share, trailing twelve months: $2.07.
Free cash flow in the twelve months to 30 June 2026: $84.0M.
Trailing P/E: 37.5×; forward P/E: 56.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CareDx, Inc. employs 761 people — $602K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CareDx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The portfolio review listed CareDx among the quarter’s most significant detractors from relative performance, while noting CareDx was not held. It also reported increased exposure to Health Care and decreased exposure to Industrials.
Why it matters — CDNA watchers may note that the review cited CareDx’s relative-performance impact despite the portfolio not holding the stock.
Baron Discovery Fund reported initiating a position in Jersey Mike’s Subs and participating in Lyntris’s IPO during the quarter. It also sold its Wingstop position to reallocate proceeds to other restaurant companies.
Why it matters — The excerpt describes portfolio activity in restaurant and defense companies and does not mention CareDx, so it provides no direct company-specific information for CDNA watchers.
CareDx raised its 2026 revenue and profit outlook, citing stronger transplant testing demand and accelerating NavDx growth. The company also expects new molecular diagnostics launches in 2027.
Why it matters — The updated outlook and reported testing growth are relevant to CDNA watchers tracking the company’s business momentum and planned diagnostics launches.
CareDx announced that a third analysis from its Kidney Allograft Outcomes AlloSure Registry (KOAR) was published in the journal Transplantation. The analysis examined the relationship between early post-transplant AlloSure Kidney donor-derived cell-free DNA levels and an outcome; the excerpt ends before specifying the outcome.
Why it matters — The publication adds a new analysis to the evidence associated with CareDx’s AlloSure Kidney test and its multicenter KOAR study.
The Motley Fool reports that CareDx stock soared today. The excerpt describes CareDx as a leader in medical diagnostics and says it is working to bring its non-invasive tests to new markets.
Why it matters — CDNA watchers may note the reported stock move alongside the company’s efforts to expand the markets for its non-invasive tests.
The 7 Wall Street analysts covering CareDx, Inc. have a median 12-month price target of $91, with estimates ranging from $90 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering CareDx, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CareDx, Inc. 89 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, CareDx, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +6.0% from the last close, and Ticker Nerd's factor model ranks CareDx, Inc. 89 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CareDx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $100 over the next 12 months.
CareDx, Inc. returned +491.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
CareDx, Inc. is a transplant diagnostics and healthcare technology company focused on improving care for organ and stem cell transplant recipients.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review". The portfolio review listed CareDx among the quarter’s most significant detractors from relative performance, while noting CareDx was not held. It also reported increased exposure to Health Care and decreased exposure to Industrials.
CareDx, Inc. is a transplant diagnostics and healthcare technology company focused on improving care for organ and stem cell transplant recipients. Its current offerings include AlloSure donor-derived cell-free DNA tests for kidney, heart, and lung transplantation, AlloMap gene-expression profiling for heart transplant patients, and HeartCare, which combines complementary biological insights to support transplant monitoring. The company also provides HistoMap Kidney for analyzing rejection in biopsy tissue and AlloHeme for monitoring relapse in certain blood cancers. Its broader portfolio includes high-resolution human leukocyte antigen typing, chimerism testing, cell-therapy monitoring, and transplant-management software such as Ottr and MedActionPlan. CareDx serves transplant centers, clinicians, laboratories, and patients by combining molecular diagnostics, laboratory services, and digital tools. Through this integrated model, CareDx occupies a specialized role in precision medicine, supporting post-transplant surveillance, rejection assessment, treatment decisions, and long-term organ health.
CEO Mr. John Walter Hanna Jr. · 761 employees · United States · https://caredx.com
